These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2399565)

  • 21. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of prolactin, CA 15-3 and TPA in breast carcinomas.
    Bhatavdekar JM; Trivedi SN; Shah NG; Patel DD; Karelia NH; Shukla MK; Ghosh N; Vora HH
    Int J Biol Markers; 1989; 4(3):150-6. PubMed ID: 2614083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma.
    Byrne J; Horgan PG; England S; Callaghan J; Given HF
    Eur J Surg Oncol; 1992 Jun; 18(3):230-4. PubMed ID: 1607033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma.
    Wobbes T; Thomas CM; Segers MF; Nagengast FM
    Cancer; 1992 Apr; 69(8):2036-41. PubMed ID: 1544112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue polypeptide antigen in tumor cytosol: a new prognostic indicator in primary breast cancer.
    Gion M; Mione R; Gatti C; Dittadi R; Leon A; Castiglioni C; Nascimben O; Bruscagnin G
    Breast Cancer Res Treat; 1990 Nov; 17(1):15-21. PubMed ID: 1965704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Brandes A; Vinante O; Bruscagnin G
    Eur J Cancer; 1992; 29A(1):66-9. PubMed ID: 1445748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of mucinous-like carcinoma associated antigen (MCA) in breast pathology: comparison with carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA).
    Saccani Jotti G; Fontanesi M; Colombo A; Valtolina M; Tardini A
    Int J Biol Markers; 1990; 5(3):145-52. PubMed ID: 2286779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
    Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
    Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
    Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucin-like carcinoma-associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring.
    Molina R; Jo J; Filella X; Zanon G; Grau JJ; Joseph J; Bedini JL; Biete A; Ballesta AM
    Int J Biol Markers; 1993; 8(2):113-23. PubMed ID: 8366294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of tumor markers in breast cancer patients].
    Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
    Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
    Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
    Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen.
    Kopczyński Z; Thielemann A
    Eur J Gynaecol Oncol; 1998; 19(5):503-7. PubMed ID: 9863926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum (circulating) tumor markers for breast cancer.
    Hayes DF
    Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
    Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F
    Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.